Literature DB >> 19033531

Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon.

Andrei Sibaev1, Birol Yüce, Markus Kemmer, Luc Van Nassauw, Ulli Broedl, Hans D Allescher, Burkhard Göke, Jean-Pierre Timmermans, Martin Storr.   

Abstract

Cannabinoid-1 (CB(1)) receptors on myenteric neurons are involved in the regulation of intestinal motility. Our aim was to investigate CB(1) receptor involvement in ascending neurotransmission in mouse colon and to characterize the involved structures by functional and morphological means. Presence of the CB(1) receptor was investigated by RT-PCR, and immunohistochemistry was used for colabeling studies. Myenteric reflex responses were initiated by electrical stimulation (ES) at different distances, and junction potentials (JP) were recorded from circular smooth muscle cells by intracellular recording in an unpartitioned and a partitioned recording chamber. In vivo colonic propulsion was tested in wild-type and CB(1)(-/-) mice. Immunostaining with the cytoskeletal marker peripherin showed CB(1) immunoreactivity both on Dogiel type I and type II neurons. Further neurochemical characterization revealed CB(1) on choline acetyltransferase-, calretinin-, and 5-HT-immunopositive myenteric neurons, but nitrergic neurons appeared immunonegative for CB(1) immunostaining. Solitary spindle-shaped CB(1)-immunoreactive cells in between smooth muscle cells lacked specific markers for interstitial cells of Cajal or glial cells. ES elicited neuronally mediated excitatory JP (EJP) and inhibitory JP. Gradual increases in distance resulted in a wave-like EJP with EJP amplitudes being maximal at the location of stimulating electrode 6 and a maximal EJP projection distance of approximately 18 mm. The CB(1) receptor agonist WIN 55,212-2 reduced the amplitude of EJP and was responsible for shortening the oral spreading of the excitatory impulse. In a partitioned chamber, WIN 55,212-2 reduced EJP at the separated oral sites, proving that CB(1) activation inhibits interneuron-mediated neurotransmission. These effects were absent in the presence of the CB(1) antagonist SR141716A, which, when given alone, had no effect. WIN 55,212-2 inhibited colonic propulsion in wild-type mice but not in SR141716A-pretreated wild-type or CB(1)(-/-) mice. Activation of the CB(1) receptor modulates excitatory cholinergic neurotransmission in mouse colon by reducing amplitude and spatial spreading of the ascending electrophysiological impulses. This effect on electrophysiological spreading involves CB(1)-mediated effects on motor neurons and ascending interneurons and is likely to underlie the here reported in vivo reduction in colonic propulsion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19033531     DOI: 10.1152/ajpgi.90274.2008

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  17 in total

1.  Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea.

Authors:  B S Wong; M Camilleri; D Eckert; P Carlson; M Ryks; D Burton; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2012-01-30       Impact factor: 3.598

2.  Expression and function of NIK- and IKK2-binding protein (NIBP) in mouse enteric nervous system.

Authors:  Y Zhang; D Bitner; A A Pontes Filho; F Li; S Liu; H Wang; F Yang; S Adhikari; J Gordon; S Srinivasan; W Hu
Journal:  Neurogastroenterol Motil       Date:  2013-09-09       Impact factor: 3.598

3.  Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity.

Authors:  Sabine Klein; Barbara Seidler; Anna Kettenberger; Andrei Sibaev; Michael Rohn; Robert Feil; Hans-Dieter Allescher; Jean-Marie Vanderwinden; Franz Hofmann; Michael Schemann; Roland Rad; Martin A Storr; Roland M Schmid; Günter Schneider; Dieter Saur
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

4.  Myenteric neurons of the mouse small intestine undergo significant electrophysiological and morphological changes during postnatal development.

Authors:  Jaime Pei Pei Foong; Trung V Nguyen; John B Furness; Joel C Bornstein; Heather M Young
Journal:  J Physiol       Date:  2012-02-27       Impact factor: 5.182

5.  Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

Authors:  Banny S Wong; Michael Camilleri; Irene Busciglio; Paula Carlson; Lawrence A Szarka; Duane Burton; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2011-07-29       Impact factor: 22.682

6.  Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.

Authors:  M A Storr; M Bashashati; C Hirota; V K Vemuri; C M Keenan; M Duncan; B Lutz; K Mackie; A Makriyannis; W K Macnaughton; K A Sharkey
Journal:  Neurogastroenterol Motil       Date:  2010-02-24       Impact factor: 3.598

7.  In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.

Authors:  R Abalo; C Chen; G Vera; J Fichna; G A Thakur; A E López-Pérez; A Makriyannis; M I Martín-Fontelles; M Storr
Journal:  Neurogastroenterol Motil       Date:  2015-09-20       Impact factor: 3.598

Review 8.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

9.  Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.

Authors:  S Grassin-Delyle; E Naline; A Buenestado; C Faisy; J-C Alvarez; H Salvator; C Abrial; C Advenier; L Zemoura; P Devillier
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

10.  Heme deficiency of soluble guanylate cyclase induces gastroparesis.

Authors:  S M R Cosyns; I Dhaese; R Thoonen; E S Buys; A Vral; P Brouckaert; R A Lefebvre
Journal:  Neurogastroenterol Motil       Date:  2013-03-28       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.